Evidence map›Paper›PMID 37632288›Full record

ArticleAnnals of neurology2023

Detection of High-Risk Paraneoplastic Antibodies against TRIM9 and TRIM67 Proteins.

Christopher M Bartley, Thomas T Ngo, Le Duy Do, Anastasia Zekeridou, Ravi Dandekar, Sergio Muñiz-Castrillo, Bonny D Alvarenga, Kelsey C Zorn, Asritha Tubati, Anne-Laurie Pinto and 17 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 5 institutions in 2 countries.

Christopher M BartleyWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-1391-4130
Thomas T NgoWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Le Duy DoFrench Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon and SynatAc Team, Institut Mechanisms in Integrated Life Sciences, L'Institut national de la santé et de la recherche médicale, U1314/CNRS UMR 5284, Universités de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Anastasia ZekeridouDepartment of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-1960-9065
Ravi DandekarWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Sergio Muñiz-CastrilloFrench Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon and SynatAc Team, Institut Mechanisms in Integrated Life Sciences, L'Institut national de la santé et de la recherche médicale, U1314/CNRS UMR 5284, Universités de Lyon, Université Claude Bernard Lyon 1, Lyon, France.ORCID 0000-0001-5958-3288
Bonny D AlvarengaWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Kelsey C ZornDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.
Asritha TubatiWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Anne-Laurie PintoFrench Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon and SynatAc Team, Institut Mechanisms in Integrated Life Sciences, L'Institut national de la santé et de la recherche médicale, U1314/CNRS UMR 5284, Universités de Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Weston D BrowneWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Patrick W HullettWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Mark TerrelongeWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Ryan D SchubertWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Amanda L PiquetDepartment of Neurology, University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, CO, USA.
Binxia YangDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Mayra MontalvoDepartment of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
Andrew F KungPhD Degree Program in Biological and Medical Informatics, School of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Sabrina A MannDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.
Maulik P ShahWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Michael D GeschwindWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Jeffrey M GelfandWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Joseph L DeRisiDepartment of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.
Sean J PittockDepartment of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-6140-5584
Jérôme HonnoratFrench Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon and SynatAc Team, Institut Mechanisms in Integrated Life Sciences, L'Institut national de la santé et de la recherche médicale, U1314/CNRS UMR 5284, Universités de Lyon, Université Claude Bernard Lyon 1, Lyon, France.ORCID 0000-0002-4721-5952
Samuel J PleasureWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
Michael R WilsonWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-8705-5084
University of California, San Francisco · USUniversité Claude Bernard Lyon 1 · FRMayo Clinic · USMayo Clinic in Arizona · USUniversity of Colorado Anschutz Medical Campus · US

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alan Ashworth · 1999 to 2026
$209.7M
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1M
Predicting progression of human prion diseaseR01AG031189 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GESCHWIND, MICHAEL D · 2008 to 2017
$5.7M
Tracking longitudinal change in presymptomatic genetic prion disease (TLC-Pre-gPrD)R01AG062562 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GESCHWIND, MICHAEL D · 2019 to 2023
$5.4M
ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
TRAINING THE NEXT GENERATION OF MENTAL HEALTH RESEARCHERSR25MH060482 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DANIEL H MATHALON, Susan M. Voglmaier · 2000 to 2026
$5.2M
Autoimmune Encephalitis - Ataxia and Psychiatric Disease: Identifying and Characterizing Novel Antibody TargetsR01MH122471 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOSEPH L. DERISI, SAMUEL JEREMY PLEASURE · 2020 to 2026
$4.7M
Next-Generation Diagnostics for Acute EncephalitisK08NS096117 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WILSON, MICHAEL R · 2017 to 2021
$999k
Illumina NovaSeq 6000 Sequencing SystemS10OD028511 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHOW, ERIC D · 2020 to 2020
$583k
Wide field-of-view Spinning Disk Confocal with Photoactivation and PhotobleachingS10OD017993 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI THORN, KURT · 2015 to 2015
$274k
NCI NIH HHS P30 CA082103NCI NIH HHS P30CA082103NIA NIH HHS P01 AG019724NIA NIH HHS P50 AG023501NIA NIH HHS R01 AG031189NIA NIH HHS R01 AG062562NIGMS NIH HHS R01 GM129325NIH HHS S10 OD017993NIH HHS S10 OD028511NIMH NIH HHS R01 MH122471NIMH NIH HHS R01MH122471NIMH NIH HHS R25 MH060482NIMH NIH HHS R25MH060482NINDS NIH HHS K08 NS096117NINDS NIH HHS K08NS096117
6 · The paper itself

Abstract

objectiveCo-occurring anti-tripartite motif-containing protein 9 and 67 autoantibodies (TRIM9/67-IgG) have been reported in only a very few cases of paraneoplastic cerebellar syndrome. The value of these biomarkers and the most sensitive methods of TRIM9/67-IgG detection are not known.

methodsWe performed a retrospective, multicenter study to evaluate the cerebrospinal fluid and serum of candidate TRIM9/67-IgG cases by tissue-based immunofluorescence, peptide phage display immunoprecipitation sequencing, overexpression cell-based assay (CBA), and immunoblot. Cases in which TRIM9/67-IgG was detected by at least 2 assays were considered TRIM9/67-IgG positive.

resultsAmong these cases (n = 13), CBA was the most sensitive (100%) and revealed that all cases had TRIM9 and TRIM67 autoantibodies. Of TRIM9/67-IgG cases with available clinical history, a subacute cerebellar syndrome was the most common presentation (n = 7/10), followed by encephalitis (n = 3/10). Of these 10 patients, 70% had comorbid cancer (7/10), 85% of whom (n = 6/7) had confirmed metastatic disease. All evaluable cancer biopsies expressed TRIM9 protein (n = 5/5), whose expression was elevated in the cancerous regions of the tissue in 4 of 5 cases.

interpretationTRIM9/67-IgG is a rare but likely high-risk paraneoplastic biomarker for which CBA appears to be the most sensitive diagnostic assay. ANN NEUROL 2023;94:1086-1101.

Indexed as

Nerve Tissue ProteinsParaneoplastic Cerebellar DegenerationAutoantibodiesBiomarkersHumansImmunoglobulin GRetrospective StudiesAutoantibodiesBiomarkersImmunoglobulin GNerve Tissue Proteins

Identifiers

PMID37632288
PMCPMC10842626
OpenAlexW4386188201

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.